Targeting PIM Kinases to Overcome Therapeutic Resistance in Cancer

Abstract Cancer progression and the onset of therapeutic resistance are often results uncontrolled activation survival kinases. The proviral integration for Moloney murine leukemia virus (PIM) kinases oncogenic serine/threonine that regulate tumorigenesis by phosphorylating a wide range substrates control cellular metabolism, proliferation, survival. Because their broad impact on processes facilitate metastasis in many cancer types, it has become clear PIM is significant driver to various types anticancer therapies. As result, efforts target therapy have intensified recent years. Clinical preclinical studies indicate pharmacologic inhibition potential significantly improve efficacy standard targeted This review focuses signaling pathways through which promote therapy, as well highlights biological contexts promising strategies exploit cancer.